Lipid lowering medication and hepatotoxicity

Journal of Internal Medicine

Volumn 250, Issue 3, 2001, Pages 183-185

  Kinnman, N ^a   Hultcrantz, R ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CIPROFIBRATE; DNA; FENOFIBRATE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID PEROXIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PLATELET DERIVED GROWTH FACTOR BB; RETINOL; STATIN; TRANSFORMING GROWTH FACTOR BETA; TROGLITAZONE;

CELL ACTIVATION; DRUG SAFETY; EDITORIAL; HUMAN; KUPFFER CELL; LIPID LIVER LEVEL; LIVER CANCER; LIVER CELL; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; LIVER FUNCTION TEST; LIVER HEMORRHAGE; LIVER TOXICITY; MUSCLE WEAKNESS; MYALGIA; NAUSEA; PORTAL HYPERTENSION; PREVALENCE; PRIORITY JOURNAL; STELLATE CELL; VOMITING;

ANTICHOLESTEREMIC AGENTS; HEPATITIS, CHRONIC; HEPATITIS, TOXIC; HUMANS; LIVER CIRRHOSIS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0035721965     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.2001.00887.x     Document Type: Editorial

References (13)

1. Hepatotoxicity in drug development: Detection, significance and solutions
2. Drug-induced liver diseases
3. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury
4. Criteria of drug-induced liver disorders. Report of an international consensus meeting
5. The pharmacokinetics and pharmacodynamics of agents proven to raise high-density lipoprotein cholesterol
6. Chronic active cirrhogenic hepatitis induced by fenofibrate
7. Chronic active hepatitis associated with antinuclear antibodies induced by fenofibrate
8. Acute severe fibrosing hepatitis associated with ciprofibrate treatment
9. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia
10. Methotrexate-induced liver cirrhosis. Clinical, histological and serological studies - A further 10-year follow-up
11. Serum type III procollagen aminopeptide for assessing liver damage in methotrexate-treated psoriatic patients
12. Use and monitoring of 'statin' lipid-lowering drugs compared with guidelines